This segment focuses on the development, production, and commercialization of in vitro diagnostic reagents and instruments for the detection of various infectious diseases. The company's R&D efforts are directed towards improving the sensitivity, specificity, and speed of diagnostic assays. Technologies employed include ELISA, rapid tests, chemiluminescence immunoassays, and automated immunoassays. Therapeutic areas covered include COVID-19, HIV, Hepatitis (A, B, C, E), EV-71, and Tuberculosis. These diagnostics play a crucial role in early disease detection, patient management, and public health surveillance. Wantai BioPharm aims to maintain its market position by continuously innovating and expanding its diagnostic product portfolio. Future opportunities include developing point-of-care diagnostics and expanding into new geographic markets. Regulatory compliance and clinical validation are essential aspects of this segment.

This segment is dedicated to the research, development, and manufacturing of vaccines for the prevention of infectious diseases. The company's R&D activities involve the use of recombinant DNA technology and other advanced biotechnological approaches to develop novel vaccines. Key products include the Hepatitis E vaccine and the Human Papillomavirus (HPV) vaccine. These vaccines address significant public health needs by preventing liver disease and cervical cancer, respectively. Wantai BioPharm is committed to improving vaccine efficacy, safety, and accessibility. Future growth opportunities include expanding the vaccine pipeline to cover other prevalent infectious diseases and exploring new vaccine delivery methods. Clinical trials and regulatory approvals are critical milestones in this segment.